Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Immunovant ( (IMVT) ) just unveiled an announcement.
On September 3, 2025, Immunovant announced promising six-month off-treatment data from its Graves’ Disease proof-of-concept study, showing that approximately 80% of patients maintained normal thyroid function, with 50% achieving anti-thyroid drug-free remission. This data suggests potential for a new treatment paradigm for uncontrolled Graves’ Disease, with two registrational trials for IMVT-1402 currently enrolling, aiming for topline results in 2027.
The most recent analyst rating on (IMVT) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Immunovant stock, see the IMVT Stock Forecast page.
Spark’s Take on IMVT Stock
According to Spark, TipRanks’ AI Analyst, IMVT is a Neutral.
Immunovant’s stock score is primarily impacted by substantial financial weaknesses, including ongoing losses and cash flow issues. Technical indicators are bearish, further weighing on the stock’s attractiveness. However, recent positive clinical trial results and leadership changes provide some optimism, potentially strengthening the company’s pipeline and long-term prospects.
To see Spark’s full report on IMVT stock, click here.
More about Immunovant
Immunovant, Inc. is a clinical-stage immunology company focused on developing targeted therapies for autoimmune diseases, leveraging anti-FcRn technology to address complex and variable patient needs.
Average Trading Volume: 1,294,142
Technical Sentiment Signal: Sell
Current Market Cap: $2.56B
See more data about IMVT stock on TipRanks’ Stock Analysis page.